Attached files

file filename
10-Q/A - 10-Q/A - BioRestorative Therapies, Inc.v232728_10qa.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R3.htm
EXCEL - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - BioRestorative Therapies, Inc.R11.htm
v2.3.0.11
Business Organization and Nature of Operations
6 Months Ended
Jun. 30, 2011
Business Organization and Nature of Operations
Note 1 - Business Organization and Nature of Operations
 
BioRestorative Therapies, Inc., formerly Stem Cell Assurance, Inc. (and including its subsidiaries, the “Company”), is a development stage enterprise whose primary activities since inception have been the research and development of its business plan, negotiating strategic alliances and other agreements, and raising capital.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of June 30, 2011, for the three and six months ended June 30, 2011 and 2010 and for the period from December 30, 2008 (inception) to June 30, 2011. The results of operations for the three and six months ended June 30, 2011 are not necessarily indicative of the operating results for the full year ending December 31, 2011. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related disclosures of the Company as of December 31, 2010 and for the year then ended, and for the period from December 30, 2008 (inception) to December 30, 2010, which were filed with the Securities and Exchange Commission on Form 10/A on July 11, 2011.

On February 1, 2011, the Company formed Stem Cell Cayman Ltd. (“Cayman”) as a wholly-owned subsidiary in the Cayman Islands.